← All trials
NCT05844501
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- May 6, 2023
- Last posted
- Oct 17, 2023
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Indiana UniversityLead sponsor
- American Heart AssociationCollaborator
- Indiana UniversityReponsible party - principal investigator
- Purdue UniversityCollaborator
- Purdue UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.